We’re proud to share that as of March 1st, dr. Ingrid de Visser-Kamerling has officially stepped into the role of Chief Operating Officer at INFECTA.
INFECTA was founded by Prof. dr. Meta Roestenberg and dr. Ingrid de Visser-Kamerling together with InFECT-NL and partners from a shared conviction: that the Netherlands needs a strong, dedicated infrastructure for infectious disease research. Because infectious diseases don’t stop at borders, and our response shouldn’t either.
From the very beginning, the vision of Ingrid and Meta has been clear: to create a place where high-quality early-phase clinical trials that include Controlled Human Infection Model (CHIM) studies and first in human studies, can be conducted and supported by a dedicated infection unit that operates day and night, even during a pandemic. Ensuring that the development of vaccines and treatments never has to slow down when it matters most.
As a spin-out of the Centre for Human Drug Research (CHDR), INFECTA is fully focused on accelerating infectious disease product development through innovative clinical research and a broad portfolio of Controlled Human Infection Models.
Alongside this role, Ingrid will continue working parttime as Research Director Infectious Diseases at CHDR, helping to ensure strong alignment and collaboration between both environments.
We’re excited to continue building this vision together.